索拉非尼、粒细胞集落刺激因子与普乐沙福联合治疗复发/难治性FLT3-ITD突变急性髓系白血病的1期研究
这项1期研究纳入28例复发/难治性FLT3-ITD突变急性髓系白血病患者,采用索拉非尼(400、600、800 mg每日两次)、粒细胞集落刺激因子(G-CSF)与普乐沙福联合方案,每两天给药一次共7剂。4周剂量限制性毒性窗口内未见剂量限制性毒性,但窗口外出现手足综合征和皮疹,多数患者需减量。意向治疗人群缓解率为36%,作者认为该联合策略有前景,需在一线治疗中进一步评估。
要点
- 28例复发/难治性FLT3-ITD突变AML患者接受索拉非尼联合G-CSF与普乐沙福治疗,扩展期选择索拉非尼800 mg每日两次。
- 4周剂量限制性毒性窗口内未见剂量限制性毒性,窗口外出现手足综合征和皮疹,多数患者需减量。
- 意向治疗人群缓解率36%(完全缓解4例、血小板未完全恢复的完全缓解4例、血细胞未完全恢复的完全缓解1例、部分缓解1例)。
核心结论
- 联合抑制FLT3激酶与基质黏附相互作用在复发/难治性FLT3-ITD突变急性髓系白血病中显示出有前景的活性,值得在一线治疗中进一步评估。
研究设计与样本
- 1期研究,2010年12月至2013年12月在三家中心纳入28例复发/难治性FLT3-ITD突变急性髓系白血病患者。
- 索拉非尼设400、600、800 mg每日两次三个剂量水平,G-CSF与普乐沙福自第1天起每两天给药一次共7剂。
- 扩展期选择索拉非尼800 mg每日两次。
主要发现
- 4周剂量限制性毒性窗口内未见剂量限制性毒性;窗口外出现手足综合征和皮疹,多数患者需减量。
- 意向治疗人群缓解率为36%(完全缓解4例、血小板未完全恢复的完全缓解4例、血细胞未完全恢复的完全缓解1例、部分缓解1例)。
- 治疗使原始细胞和CD34/38-干/祖细胞向循环的平均动员倍数分别为58.4倍和47倍。
- 循环白血病细胞上CXCR4、CD44和VLA4的表达与CD34+/38-、CD34+/38-/123+「祖」细胞的动员呈负相关(所有P≤0.002)。
- 对两例患者连续样本的质谱流式分析显示,耐药早期即出现于持续Akt和/或ERK信号传导的亚克隆。
局限性
- 作者在结论中指出该策略值得在一线治疗中进一步评估,提示现有数据来自复发/难治性人群、需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Stroma-leukemia interactions mediated by CXCR4, CD44, VLA4, and their respective ligands contribute to therapy resistance in FLT3-ITD-mutated acute myelogenous leukemia (AML). We conducted a phase 1 study with the combination of sorafenib (a FLT3-ITD inhibitor), plerixafor (a SDF-1/CXCR4 inhibitor), and G-CSF (that cleaves SDF-1, CD44, and VLA4). Twenty-eight patients with relapsed/refractory FLT3-ITD-mutated AML were enrolled from December 2010 to December 2013 at three dose levels of sorafenib (400, 600, and 800 mg twice daily) and G-CSF and plerixafor were administered every other day for seven doses starting on day one. Sorafenib 800 mg twice daily was selected for the expansion phase. While no dose-limiting toxicities (DLT) were encountered in the four-week DLT window, hand-foot syndrome and rash were seen beyond the DLT window, which required dose reductions in most patients. The response rate was 36% (complete response (CR) = 4, complete remission with incomplete platelet recovery (CRp) = 4, complete remission with incomplete hematologic recovery (CRi) = 1, and partial response (PR) = 1) for the intention to treat population. Treatment resulted in 58.4 and 47 mean fold mobilization of blasts and CD34 /38- stem/progenitor cells, respectively, to the circulation. Expression of the adhesion molecules CXCR4, CD44, and VLA4 on circulating leukemia cells correlated negatively with the mobilization of CD34+/38-, CD34+/38-/123+ "progenitor" cells (all P ≤ .002). Mass cytometry analysis of sequential samples from two patients demonstrated resistance emerging early on from sub-clones with persistent Akt and/or ERK signaling. In conclusion, the strategy of combined inhibition of FLT3 kinase and stromal adhesive interactions has promising activity in relapsed/refractory, FLT3-ITD-mutated AML, which warrants further evaluation in the front-line setting.
引用
- Borthakur G, Zeng Z, Cortes JE, et al. Phase 1 study of combinatorial sorafenib, G-CSF, and plerixafor treatment in relapsed/refractory, FLT3-ITD-mutated acute myelogenous leukemia patients. Am J Hematol. 2020. PMID: 32697348. doi:10.1002/ajh.25943
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。